All In Biotech

Drug Trial Radar · NCT07928167

Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients

A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 25, 2025

Primary completion

Jan 15, 2027

Study completion Jan 1, 2028

Sponsor

Lead sponsor
Kidney Cancer Research BureauAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.

Conditions

  • Metastatic Renal Cell Carcinoma ( mRCC)

Interventions

  • LenvatinibDrug

    20 mg orally once daily.

  • PembrolizumabDrug

    200 mg intravenously every 3 weeks

  • Stereotactic Body Radiation Therapy (SBRT)Radiation

    The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Response of unirradiated lesions according to RECIST v1.1Time frame: Percentage of patients with response at week 12

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Republican Dispensary of Tatarstan

    Kazan', Russia · Recruiting

  • N.N. Blokhin National Medical Research Center of Oncology

    Moscow, Russia · Recruiting

  • STOONCO clinic

    Moscow, Russia · Recruiting

  • Orenburg Regional Cancer Center

    Orenburg, Russia · Recruiting

  • SBHI Leningrad Regional Clinical Hospital

    Saint Petersburg, Russia · Recruiting

  • Cancer Center "Medical City"

    Tyumen, Russia · Recruiting

  • Republican Clinical Oncology Dispensary

    Ufa, Russia · Recruiting

  • "ErSpace" Radiation Therapy Center

    Ulyanovsk, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.